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Abstract
Acute liver failure is a rare and devastating clinical 
condition. At present, emergency liver transplantation is 
the only life-saving therapy in advanced cases, yet the 
feasibility of transplantation is affected by the presence 
of systemic inflammation, infection and resultant multi-
organ failure. The importance of immune dysregulation 
and acquisition of infection in the pathogenesis of acute 
liver failure and its associated complications is now 
recognised. In this review we discuss current thinking 
regarding the role of infection and inflammation in the 
pathogenesis of and outcome in human acute liver 
failure, the implications for the management of such 
patients and suggest directions for future research.
Key words: Inflammation; Neuroinflammation; Acute 
liver failure; Biomarker; Infection
© The Author(s) 2016. Published by Baishideng Publishing 
Group Inc. All rights reserved.
Core tip: Acute liver failure is a serious and rare 
condition, for which emergency liver transplantation is 
the only rescue therapy in advanced cases. The medical 
need for liver transplantation and feasibility of such an 
intervention are affected by the presence of systemic 
inflammation and infection. This review will discuss 
current thinking with regards to the role of infection 
and inflammation in the pathogenesis of human acute 
liver failure, and its effect on outcome. We also provide 
clinical guidance for the management of these patients 
and suggest directions for future research.
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Gastroenterol 2016; 22(26): 5958-5970  Available from: URL: 
http://www.wjgnet.com/1007-9327/full/v22/i26/5958.htm  DOI: 
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INTRODUCTION
Acute liver failure (ALF) is a rare and devastating 
clinical condition, resulting from massive loss of 
hepatic parenchyma and metabolic function. ALF is 
estimated to affect 2000 people per year in the United 
States, and is associated with a significant mortality 
rate[1,2]. The development of hepatic encephalopathy 
(HE) defines ALF, and confers a poor prognosis. With 
the use of emergency liver transplantation, up to 75% 
of patients should now be expected to survive[3,4]. 
Acetaminophen (APAP; paracetamol) is the most 
common cause of ALF in the West, compared with viral 
causes in the developing world. 
Many of the extra-hepatic features of ALF-including 
hemodynamic disturbance and multi-organ failure- are 
now thought to be driven by the secondary immune 
response to hepatocyte cell death. Clinically ALF 
shares many features with severe sepsis, including 
a systemic inflammatory response and progression 
to multi-organ failure. The hemodynamic profile of 
ALF mirrors that of septic shock, suggesting that the 
systemic release of inflammatory mediators might be 
responsible for progression from the inflammatory 
response to multi-organ failure. Immune dysregulation 
is now recognised to be central to the pathogenesis 
of ALF[5,6] and it is likely that the clinical features 
and outcomes in ALF relate to an individual patients 
innate immune response to liver injury, as opposed 
to the liver injury and hepatocyte cell death itself. 
As a result of this immune dysregulation, patients 
with ALF demonstrate increased susceptibility to 
infection which is associated with the development 
of further complications. Currently, emergency liver 
transplantation is the only rescue therapy for patients 
with advanced ALF, yet the development of infection, 
sepsis and the resultant inflammatory response and 
multi-organ failure may preclude the opportunity for 
life-saving liver transplantation. Novel, non-transplant 
therapies are urgently needed, and understanding the 
role of infection and inflammation in the pathogenesis 
and progression of ALF is central to the development 
of new therapeutic strategies. Understanding the role 
and interplay of infection and inflammation in the 
pathogenesis of ALF will in addition allow better risk 
stratification and prognostication in ALF. In this review 
we detail the current thinking with regards to the role 
of infection and inflammation in the pathogenesis of 
and outcome in human ALF, their implications for the 
management of the ALF patient and suggest directions 
for future research. Comprehensive overviews of 
human basic science and research studies undertaken 
in animal models of ALF are out with the scope of this 
review. 
ImmUNe DysfUNCTION IN ALf
The immune dysregulation in ALF has been discussed 
extensively elsewhere[5-7]. Dysfunction of both the 
cellular and humoral innate immune system plays a 
role in the pathophysiological development of ALF. 
Defective functioning of the cellular components in 
particular of the innate immune system are implicated 
in the increased risk of infection in patients with ALF. 
Causes of innate immune dysfunction are proposed to 
include changes in gut permeability, endotoxinemia, 
lipoprotein and albumin dysfunction, and toll-like 
receptor (TLR) expression[8]. Toll like receptors are 
innate pattern recognition receptors, present in many 
cells including neutrophils and hepatocytes. Activation 
of neutrophil TLR can induce an inflammatory response 
with phagocytic activity and cytokine release, but 
whether this is beneficial or detrimental to the patient 
with ALF is not well defined[9]. 
The underlying mechanism of acute liver injury 
begins with hepatocyte necrosis. The driver of ongoing 
necrosis in the absence of ongoing injury is not clearly 
understood. Oxidative stress leads to production of 
reactive oxygen species, which in turn via a cascade of 
events results in activation of c-Jun N-terminal kinase 
(JNK). This is turn leads to mitochondrial dysfunction 
causing further hepatocyte necrosis and release of 
damage associated molecular patterns (DAMPs). 
DAMPS activate hepatic macrophages and as a 
further consequence the inflammasome is formed. 
Comprehensive reviews of the role of inflammasomes 
in liver disease are available elsewhere[10,11]. Briefly, 
inflammasomes are multiprotein complexes that sense 
intracellular danger signals via NOD-like receptors. 
The inflammasome finely controls the inflammatory 
response, by responding to low-threshold signals. 
Activation of the inflammasome by DAMPS is a result 
of TLR activation and activation by an inflammasome 
ligand, and results in caspase-1 activation and IL-1β 
secretion - see Figure 1. The NLRP3 inflammasome 
is the most well characterised member of the 
inflammasome family and three potential activation 
pathways have been proposed: (1) extracellular ATP 
signal resulting in potassium efflux and pannexin 
recruitment; (2) endocytosis of crystalized cholesterol, 
uric acid or amyloid with lysosomal damage following 
phagocytosis of these particles; and (3) activation 
by reactive oxygen species. Looking specifically at 
the role of the inflammasome in acute liver failure, 
inflammasome activation in APAP-ALF has been 
studied[11]. Necrotic hepatocytes and sinusoidal 
endothelial cells release DAMPS, which activate the 
inflammasome as described above. It remains unclear 
as to whether APAP directly results in inflammasome 
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formation. The inflammasome is a determinant of 
hepatic inflammation in APAP-ALF, but its role in 
regeneration - critical in determining the outcome 
of the patient - is uncertain. Much of the research 
undertaken looking at the role of the inflammasome 
in APAP-ALF has been undertaken in mouse models, 
and therefore may not be directly applicable to human 
clinical practice. 
Subsequently, pro-inflammatory cytokines are 
released, leading to the recruitment of more immune 
cells to the site of inflammation and further advancing 
hepatocyte cell death. The roles of specific cell types 
are discussed briefly below and highlighted in more 
detail in Table 1[12-20]. A comprehensive overview of 
other pathophysiological mechanisms important in 
modulating inflammation and infection in ALF such 
as autophagic dysfunction, mitochondrial membrane 
potential dysregulation and the influence of calcium 
flux are out with the scope of this clinical review, but 
are extensively reviewed elsewhere[21-23]. 
Neutrophils
Neutrophils - a major subset of innate immune cells- 
are rapidly recruited to the liver in response to liver 
injury. With the evidence available at present, it is 
unclear as to whether neutrophils directly potentiate 
liver injury[12]. Locally, neutrophils become activa-
ted by cytokines which may result in progressive 
tissue damage via release of proteolytic enzymes 
and reactive oxygen species. In severe sepsis, a 
condition which shares many clinical features with 
ALF, systemic neutrophil activation is associated with 
a functional immune paresis. Neutrophils assist in 
removal of necrotic cell debris in preparation for tissue 
repair and resolution of the inflammatory response. 
In ALF, neutrophils have decreased phagocytic 
activity - see Table 1. This decrease in phagocytosis 
correlates with arterial ammonia concentration, 
which has been shown in several studies to predict 
the development of cerebral edema in advanced 
hepatic encephalopathy[24,25]. In summary, circulating 
neutrophils in ALF appear to have impaired bactericidal 
function, and this is likely to be relevant in the 
increased susceptibility to infection, which may 
subsequently preclude life-saving liver transplantation, 
and hence a complete understanding of the role of 
cells involved in fighting infection such as neutrophils 
is essential.
Monocytes and macrophages
Monocytes and hepatic macrophages mediate the 
inflammatory response and tissue repair process 
occurring in ALF. Kupffer cells - resident hepatic 
macrophages- potentiate liver injury by sensing DAMPs 
and releasing pro- and anti-inflammatory mediators 
(with TNF-α being relevant in sensitizing hepatocytes 
to apoptosis); however the extent of their role remains 
incompletely understood[7]. Hepatic macrophages 
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Figure 1  Activation of the NLRP3 inflammasome. NLRP3 inflammasome activation. Extracellular ATP is sensed by the P2X7 purinergic receptor and results in 
potassium efflux and recruitment of pannexin. Activation may also be induced by large particles such as uric acid, and lysosomal damage after phagocytosis of these 
particles induces NLRP3 inflammasome activation. Reactive oxygen species also contribute to inflammasome activation. Activation of the inflammasome results in 
caspase-1 and IL-1β secretion.
Lysosome damage
with a median onset of 2-5 d from admission[28]. 
More recently, infection has been reported as a later 
complication in ALF, occurring at a median of 10 
d[29]. Importantly, the presence of bacterial or fungal 
infection may preclude listing for OLT, at present the 
only curative option for advanced ALF. 
As such, the development of infection has 
significant prognostic implications. There is a complex 
and as yet not completely understood relationship 
between infection, hepatic encephalopathy (HE) and 
outcome. Rolando demonstrated that infection is more 
frequent in those with higher grades of HE and higher 
SIRS (systemic inflammatory response) score, as a 
result of the mechanisms described above[30]. It is 
often difficult however to tease out what is cause and 
effect in the relationship between HE and infection. 
Other groups have also reported a link between the 
acquisition of infection and both the development and 
progression of HE[31]. Perhaps unsurprisingly, infection 
is a leading cause of death in ALF and is responsible 
for late death in at least a quarter of cases[28,32]. 
Despite this, the development of bacteremia has 
not been consistently shown to be independently 
predictive of mortality[29]. Predictors of bacteremia in 
ALF include admission HE grade > 2, maximum HE 
grade and admission SIRS score > 1[29]. The presence 
of a SIRS response may in fact reflect the presence of 
subclinical infection, or may reflect the development 
of an inflammatory and subsequent anti-inflammatory 
response, which as discussed later in this review may 
predispose to the acquisition of infection. 
demonstrate plasticity, with their function extending 
from pro-inflammatory to pro-resolution. There is 
evidence for tolerance of circulating monocytes to 
bacterial endotoxins, which further impedes host 
immunity[26]. Liver regeneration following injury 
requires functional liver macrophages, the numbers 
of which are controlled by CSF-1 (macrophage colony 
stimulating factor). In patients with APAP-ALF, low 
serum levels of CSF-1 were associated with increased 
mortality[27]. Of note, administration of CSF-1 to mice 
increased innate immunity[27], raising the possibility 
that CSF-1 could be developed as a potential 
therapeutic target in humans. Investigating further 
the relationship between neutrophils, macrophages 
and other immune cells in human ALF would provide 
a clearer understanding of the pathophysiology of this 
condition, and potentially provide a target for urgently 
needed new therapies. 
INfeCTION AND ALf
Patients with ALF have increased susceptibility 
to both bacterial and fungal infection as a result 
of a conglomerate of factors, including reduced 
complement levels, impaired phagocytic function, 
and the need for invasive interventions. In addition, 
for example in those patients with cerebral edema, 
actions usually taken to reduce infection risk such as 
chest physiotherapy are contra-indicated due to the 
risk of exacerbating intracranial hypertension (ICH). 
Infection usually develops early in the course of ALF, 
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Table 1  Cell types and proteins involved in immune pathogenesis of acute liver failure
Ref. Cell type/protein study 
population 
Finding in ALF
Taylor et al[12] Neutrophils Significant reduction in neutrophil surface expression of CD16 (causing reduced binding 
capacity) and neutrophil phagocytic activity compared with healthy controls. Impaired 
phagocytic activity predictive of death without transplantation
ALF
Manakkat Vijay et al[13] Neutrophils Toll-like receptors sense pathogens and induce inflammatory responses. Neutrophil toll-like 
receptor 9 expression increased on day 1 compared with healthy controls, and correlated with 
severity of HE and SIRS
APAP-ALF
Srungaram et al[14] Osteopontin 
(activates neutrophils and 
macrophages)
Median osteopontin levels significantly elevated in the ALF group compared with comparator 
cohorts; median osteopontin levels were highest in patients with APAP-ALF and ischaemic 
hepatitis (conditions associated with a hyperacute course and better outcomes - osteopontin may 
have a central role to play in the resolution of ALF)ALFSG ALF
Lawson et al[15] Neutrophils Neutrophils accumulate in liver parallel to or slightly after liver injury; number of neutrophils 
in liver substantial compared with baseline, with increased levels of TNF-α, KC and MIP-2 
chemokines
APAP-ALF
Sehgal et al[16] Monocyte-macrophages Functionality of monocytes and macrophages impaired in pregnant patients developing ALF 
compared with those with ALI. Hepatitis E in Pregnancy
Wigmore et al[17] Monocytes Peripheral blood mononuclear cells from patients with ALF show reduced potential to produce 
IL-6 and TNF and elicit an acute phase response in vitroALF
Leifeld et al[18] Macrophages CC-chemokines recruit and activate macrophages and T-cells. Elevated levels of serum and 
intrahepatic chemokines in ALF compared with controls, correlating with extent of infiltration by 
macrophages and T-cells. 
ALF
dos Santos et al[19] Eosinophils High number of intrahepatic eosinophils in ALF, associated with increased expression of IL-6.
ALF
Wyke et al[20] Complement system Defective opsonisation due to complement deficiency. Complement factors reduced to below 
40% of the activity of control serumALF
ALF: Acute liver failure; APAP: Acetaminophen; SIRS: Systemic inflammatory response.
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In addition, some therapies used to treat specific 
etiologies of ALF may also lead to the development of 
infectious complications, and such treatments must be 
used with caution when there is evidence to suggest 
that the development of infection is associated with 
a poorer outcome. One Japanese group studied the 
development of infectious complications in patients 
with autoimmune ALF treated with corticosteroids; 
corticosteroids were given to 19 patients, and 17 
infectious complications were identified in 12 patients, 
at a median of 15 d[33]. Importantly, no significant 
differences in the clinical or biochemical features 
of the patients with and without infection were 
noted[33], reinforcing the need for a high index of 
clinical suspicion for infection in this group of patients. 
Another group reported opportunistic infection in 
21.6% of ALF patients receiving steroid therapy, with 
cytomegalovirus and Pneumocystis jiroveci being most 
commonly implicated[34]. 
Diagnosis of infection in ALF
In patients with ALF, the clinical signs of infection 
such as pyrexia and elevated peripheral white cell 
count are absent in up to 30% of patients[35], and 
clinical suspicion must remain high in patients with a 
deteriorating course. In addition, the hemodynamic 
profile in ALF is similar to that observed in septic shock, 
adding an extra level of complexity in distinguishing 
between the two conditions. C-reactive protein (CRP) 
- a commonly used marker of infection in other clinical 
situations- is unhelpful in the patient with ALF. CRP is 
produced exclusively by hepatocytes and therefore 
low levels are often measured in ALF consequent to 
reduced hepatic parenchyma. A low CRP therefore 
does not reflect lack of significant inflammation or 
infection; Silvestre studied 7 patients with ALF and 
sepsis and in all septic patients, CRP levels were 
markedly decreased and on occasions undetectable[36], 
confirming the futility of CRP as a marker of infection 
in ALF. When meticulous microbiological surveillance 
is undertaken, clinical or bacteriological evidence of 
infection is found in up to 90% of patients with ALF[28]. 
Another difficulty in characterizing infections and the 
effect of antimicrobials in patients with ALF admitted 
to tertiary liver centres is that many patients are 
transferred from other units where they may have 
had microbiological cultures performed and received 
anti-microbial therapy. Often this information is not 
available and these factors may skew the results of 
studies of infection undertaken in tertiary liver centres. 
Bacterial infection
Bacterial infections are most common, documented in 
30%-80% of ALF patients[28,35,37]. Since the description 
of ALF as a disease entity, both the timing of the 
development of bacteremia and the organisms isolated 
has changed (Figure 2)[28,29,37]. Older data suggested 
that bacteremia was an early complication of ALF, 
occurring at a median of 3 d[28]. More recent data 
now support the development of bacteremia as a late 
complication, with Karvellas reporting a median time to 
bacteremia of 10 d[29]. Gram positive bacteremia was 
previously most common, reported in 73% of those 
with confirmed blood stream infection[37]. However, 
Gram negative bacteremia is now more common, 
identified in 52% of the Karvellas cohort[29]. This is 
of real clinical importance, as at least one study has 
identified a trend towards progression of HE in patients 
with gram negative infection compared with gram 
positive infection[31]. In general, critically ill patients are 
at increased risk of infection with antibiotic-resistant 
organisms such as vancomycin resistant enterococcus 
(VRE) and methicillin resistant Staphylococcus aureus 
(MRSA). Older reports of infection in ALF identified that 
pneumonia was the most common infection in ALF, 
accounting for 50% of all infections[28,35]. Urinary tract 
infections were the second most frequent, accounting 
for 22% of infections[28]. Gram positive bacteria were 
most commonly isolated and frequently related to 
pulmonary sepsis. In a more recent study of patients 
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Figure 2  Temporal change in infections in acute liver failure. 1Adapted from Rolando et al[28]; 2Adapted from Wade et al[37]; 3Adapted from Karvellas et al[29].
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with ALF admitted to a Liver Intensive Care Unit, 35% 
developed bacteremia[29]. The most frequently isolated 
pathogens were Enterococcus faecium, Klebsiella spp 
and vancomycin-resistant Enterococcus[29], highlighting 
a shift in organisms most commonly implicated in 
bacterial infection in ALF. This may reflect changes in 
the choice of antimicrobial prophylaxis regimens over 
time, selecting out particular and resistant organisms.
Late deaths (> 7 d) in patients with ALF are often 
attributable to superadded bacterial infection; Rolando 
reported that in their cohort, all deaths occurring 7 
d after admission were directly related to bacterial 
infection[28], highlighting the importance of remaining 
vigilant for the development of bacterial infection, 
particularly later in the course of the illness.
Fungal infection
Fungal infections are also common in the ALF patient 
cohort, occurring in around one third[38]. Candida 
species is most frequently isolated, and affected patients 
commonly have concurrent bacterial infection[38]. 
Aspergillus sp. and Pneumocystis jiroveci are also 
recognised to be opportunistic fungal infections in 
ALF[34,39]. Aggressive investigation for fungal infection 
should commence in the patient with deterioration 
in HE grade, persistent pyrexia, renal failure or a 
markedly elevated white cell count, in particular if the 
patient is already receiving and deteriorating despite 
broad spectrum antibiotics[38]. Without treatment, 
mortality with fungal infection is up to 100%[38], 
suggesting a possible role for prophylactic antifungal 
therapy. To date, no study has looked specifically and 
solely at the role of prophylactic antifungal therapy in 
ALF, and such a study may be challenging to undertake 
as the majority of patients will have concurrent 
bacterial infection which may confound results.
Viral infection
Opportunistic viral infections are common in all 
critically ill patients due to functional immunosup-
pression. In a cohort of critically ill patients due to 
a variety of etiologies requiring admission to the 
intensive care unit, cytomegalovirus (CMV) reactivation 
occurred in 33%, with CMV infection at any level 
being independently associated with death at 30 
d[40]. In the ALF cohort, viral infection appears to be 
particularly frequent in those patients receiving steroid 
therapy. One study reported that of patients who were 
receiving steroid therapy in ALF, 25.8% developed 
CMV infection[34], highlighting the importance of 
considering the development of viral infections in 
appropriate patients, particularly in those who are 
immunosuppressed. However, the clinical relevance of 
opportunistic viral infection was not discussed in this 
study, and its impact upon outcomes remains an area 
for future study.
Antimicrobial prophylaxis
Despite the plausible rationale behind giving 
prophylactic antimicrobials to reduce risk of infection 
and the associated impact on HE and outcome, there 
is no published evidence to confirm that this approach 
results in a clear mortality benefit. The Acute Liver 
Failure Study Group (ALFSG) retrospectively assessed 
the impact of antimicrobial prophylaxis (physician 
dependent and including both anti-bacterial and anti-
fungal agents) on rates of blood steam infection 
(BSI) and 21-d survival in ALF[32]. Of a cohort of 1551 
patients with ALF (the most common etiology being 
APAP), 34% had at least one episode of culture-
positive infection and 14.6% had at least one episode 
of BSI. 39% of all patients received antimicrobial 
prophylaxis; 19% of this cohort received antifungal 
therapy. Those patients receiving prophylaxis had 
higher HE grade and had a higher requirement for 
organ support, generally reflecting a sicker group of 
patients requiring more invasive therapy, and therefore 
potentially at higher risk of infection. However, there 
was no significant difference in the probability of 
developing BSI in patients receiving prophylaxis 
compared with those without prophylaxis (p = 0.12). 
In the APAP subgroup, patients receiving prophylaxis 
were more likely to proceed to transplantation, but 
there was no significant difference in overall 21-d 
survival. Looking at the whole cohort on multivariate 
analysis, antimicrobial prophylaxis did not confer a 
benefit on 21-d survival. It must also be borne in mind 
that as discussed above, empirical use of antibiotics 
may lead to the development of multidrug resistant 
organisms.
Changes in gut permeability may contribute to the 
development of infection in ALF, and therefore it has 
been proposed that selective gut decontamination with 
poorly absorbable oral antibiotics may be an effective 
method to reduce the risk of bacterial translocation 
and infection in ALF. Salmeron reported that in a 
small group of patients, the administration of poorly 
absorbable oral antibiotics significantly reduced the 
likelihood of developing infection; this reduction was 
predominantly related to a difference in the rate of 
infection from enterobacteria[41]. The clinical relevance 
of infection with this specific organism is not clear, and 
the routine use of selective intestinal decontamination 
cannot be advocated at present.
In summary, data regarding antimicrobial prophy-
laxis in ALF are limited. The ALFSG recommend that 
prophylactic antimicrobials and antifungals cannot be 
advocated in all patients - particularly those with mild 
HE - as these have not been consistently shown to 
improve overall survival rates[42]. The ALFSG advise 
that periodic surveillance cultures are undertaken and 
therapy initiated promptly according to culture results 
at the earliest indication of active infection or clinical 
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deterioration[42]. Many units therefore commence 
antimicrobials at the development of higher grade HE 
requiring intubation and ventilation, the development 
of SIRS or otherwise unexplained clinical deterioration. 
Infection and outcome
Rolando has reported upon the impact of BSI in ALF, 
with an attributable mortality of up to 60%-76%[28,30]. 
Late deaths (i.e., greater than 7 d after admission) 
may all be attributable to the acquisition of infection[28]. 
Karvellas recently demonstrated a significant increase 
in 21-d mortality in patients developing BSI, and 
this risk was higher in those patients with non-APAP 
etiology[32]. This is likely related to the often sub-acute 
and prolonged course of this illness and development 
of the compensatory anti-inflammatory response, both 
of which result in predisposition to infection. However, 
in an earlier study, Karvellas failed to demonstrate a 
significant association between the development of 
bacteremia and poorer outcome[29]. The data regarding 
the association between infection and outcome in 
ALF are therefore are somewhat conflicting, however 
clinically and pathophysiologically it is logical that the 
acquisition of infection results in a deteriorating course 
and poorer outcome.
sIRs
SIRS is the result of a clinical response to an insult 
of infectious or non-infectious origin, and occurs as a 
result of systemic pro-inflammatory (e.g., TNF-α, IL-1, 
IL-6) and anti-inflammatory (e.g., IL-10) cytokine 
release. The source of this systemic cytokine release 
may be from hepatocyte cell death and the necrotic 
liver itself, secondary to endotoxemia or impaired 
hepatic cytokine metabolism[43-45]. SIRS is defined as 
two or more of: temperature < 36 ℃ or > 38 ℃, heart 
rate > 90 beats/min, leucocyte count < 4 × 109/L 
or > 12 × 109/L and tachypnea > 20 breaths/min or 
PaCO2 < 4.3 kPa. In a general population of acutely ill 
hospitalized patients, patients with SIRS response had 
a 6.9 times higher 28-d mortality than those without 
SIRS, and the severity of SIRS correlated with the 
severity of organ dysfunction and mortality rate[46]. In 
ALF specifically, SIRS is believed to be an important 
factor in the development of renal impairment, HE, 
multi-organ failure and death.
Difficulties in utilizing SIRS in studies of ALF 
In studies of SIRS in patents with ALF, the respiratory 
component is often not included as many patients 
are ventilated and accepted respiratory parameters 
set. However, this approach is not uniform and not 
always commented upon in study methodology; this 
must be borne in mind when analyzing the results of 
any study assessing the utility of the SIRS score in 
ALF. In addition, many studies assess SIRS at a single 
time point only, whereas the true value of the score 
may come with serial measurements and assessment 
of trends. Furthermore, the appropriate cut off SIRS 
score for predicting prognosis in ALF has not been 
defined. Therefore there are limitations currently 
in using the SIRS score to predict prognosis in ALF, 
and further work is required before this score can be 
accepted as a prognostic marker in isolation, or be 
included in other validated prognostic models.  
Development of SIRS and CARS
Local tissue injury is the initiating factor in the 
development of SIRS, and this can arise from any 
number of insults in the setting of ALF. Initially, this 
injury triggers a marked release of a number of pro-
inflammatory mediators (e.g., DAMPS, TNF-α, IL-6 
and IL-8)[5] through the activation of macrophages, 
polymorphonuclear cells, endothelial cells and the 
complement system. These pro-inflammatory me-
diators are now recognized to be associated with both 
tissue regeneration and tissue damage. Circulating 
monocytes and lymphocytes are attracted to the 
area of injury, and act to increase the local response 
to injury. Platelet and coagulation cascade activation 
occurs with an increase in vascular permeability and 
spill over of pro-inflammatory mediators, which may 
in turn lead to the SIRS. Systemic pro-inflammatory 
cytokine release following local tissue injury subse-
quently results in an increase in the level of circulating 
anti-inflammatory mediators. The point at which and 
the stimulus for the switch to the production of anti-
inflammatory mediators is not well defined, but this 
counter response aims to prevent overwhelming 
systemic inflammation. This compensatory anti-
inflammatory response syndrome (CARS) is associated 
with raised levels of anti-inflammatory mediators 
(IL-4, IL-10, TGF-β), and an impairment in cellular 
immune function[5]. Monocyte deactivation is key in 
the development of CARS[47]. This CARS phase results 
in an increased risk of and decreased clearance of 
infection, and multiorgan failure[5]. 
The development of SIRS is associated with poorer 
outcomes. SIRS is associated with progression of 
HE[31,48], development of bacteremia[29] and in some 
studies a poorer outcome independent of the presence 
of infection[48,49]. Karvellas reported that on multivariate 
analysis, SIRS was not predictive of mortality either 
in ALF patients (all etiologies) developing bacteremia 
or in non-transplanted ALF patients[29]. In contrast, 
Craig demonstrated that SIRS occurred significantly 
earlier and was of a greater magnitude in patients 
with APAP- ALF who died compared with patients 
who survived, with the number of SIRS components 
fulfilled post overdose being significantly associated 
with increased mortality at 48, 72 and 96 h time 
points[49]. These data suggest that perhaps the clinical 
effect of developing SIRS is etiology specific. SIRS 
develops more frequently in APAP-ALF compared 
with non-APAP ALF[50], and this may reflect the 
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hyperacute course of APAP-ALF. The role of SIRS 
in non-APAP ALF is less well defined and is an area 
worthy of future research. Analysing all etiologies of 
ALF, Leithead identified that the presence of SIRS was 
associated with a reduced chance of spontaneous 
survival[50]. Miyake et al[48] assessed the relationship 
between SIRS and outcome in 99 patients with non-
APAP ALF. In this cohort, increasing SIRS score was 
significantly associated with the development of adult 
respiratory distress syndrome (ARDS), disseminated 
intravascular coagulation (DIC), acute renal failure 
and multi-organ failure. Patients with a SIRS score 
of 0 or 1 had a significantly higher chance of survival 
than patients with a SIRS score of 2. This group also 
demonstrated - albeit in small numbers - that using 
SIRS as a predictor of prognosis had better specificity 
and positive predictive values when compared with 
the Kings College Hospital Poor Prognostic Criteria 
(KCC)[48]. The same group analyzed the association 
between SIRS and outcome in fulminant hepatitis B 
and reported that a SIRS response was independently 
associated with 1 wk and overall mortality[51]. The 
role of SIRS in the development of HE and renal 
dysfunction will be discussed further below.
NeUROINfLAmmATION AND HepATIC 
eNCepHALOpATHy 
Progression of HE is a major determinant of outcome 
in ALF, and increasingly the presence of infection 
and/or a SIRS response is recognised to predispose 
to increasing HE grade and a poorer prognosis[30,31]. 
Following progression, patients with deeper HE are 
at greater risk of developing infection, as a result of 
poorer liver function and the invasive interventions 
required to manage their condition. 
Key mechanisms in the development of central 
nervous system (CNS) complications of ALF, including 
cerebral edema, are incompletely understood, and 
much of the basic research has been undertaken in 
animal models of ALF. Raised arterial and brain am-
monia levels- as a consequence of decreased removal 
by the liver- have been shown to correlate with the 
severity of CNS complications in ALF[52]. Ammonia 
sensitizes macrophages to activating stimuli, increasing 
the secretion of pro-inflammatory cytokines, thereby 
perpetuating the progression of HE and cerebral 
edema, yet the use of ammonia lowering therapies 
have not been consistently proven to prevent or treat 
such complications[53,54]. 
The concept of the “inflamed brain” in ALF has 
been proposed[55], and TNF-α, IL-Ib and IL-6 are 
thought to be key mediators in this process. Neuro-
inflammation may occur as a result of a direct effect 
of systemically derived pro-inflammatory cytokines 
and/or effects of local cerebral accumulation of lactate 
which subsequently causes a direct neuroinflammatory 
response[56]. Neuro-inflammation is characterized 
by microglial activation and local release of pro-
inflammatory cytokines. Increased cerebral lactate 
levels correlate with microglial activation and cerebral 
pro-inflammatory cytokine production, confirming its 
importance in the pathophysiology of HE[57]. TNF-α 
levels have been shown to be elevated in relation to 
the severity of HE in ALF[58]. Furthermore, TNF-α gene 
polymorphisms influence outcome in human ALF, and 
in the setting of APAP-ALF, decreased TNF-α production 
appears to protect against the development of severe 
HE[59]. 
There has been some debate as to whether the 
blood-brain barrier (BBB) remains intact in ALF[56,60]. 
Both permeability changes and complete breakdown of 
the BBB have been suggested. In human ALF, studies 
have failed to demonstrate structural BBB breakdown 
in contrast to the findings in murine studies[61,62]. 
However, TNF-α is known to disrupt the BBB and in 
septic encephalopathy structural BBB breakdown in 
reported[63], therefore it seems likely that some degree 
or form of BBB breakdown is intrinsically involved in 
the pathogenesis of HE in ALF. Transfer of systemic 
pro-inflammatory cytokines across a disrupted blood-
brain barrier is one proposed mechanism for the 
development of CNS complications. Further work 
is required to establish the role of the blood-brain 
barrier - and its particular its relationship with TNF-α 
in the pathogenesis of HE in human ALF, to allow the 
development of targeted therapies.
In ALF, a significant correlation is seen between both 
the presence and severity of systemic inflammation, 
and the development of CNS complications, in 
particular intracranial hypertension (ICH)[51,52]. This 
appears to be particularly relevant in cases of APAP-ALF 
and in non-infected patients, a higher number of SIRS 
components present at admission (reflecting either 
sterile inflammation or occult infection) was associated 
with a progression to deeper stage HE[31]. In patients 
requiring intervention for raised intracranial pressure 
(ICP), SIRS score and levels of IL-1β, TNF-α and IL-6 
were significantly higher than in patients not requiring 
therapy for raised ICP[52]. TNF-α levels correlated 
with cerebral blood flow (rapid increases in which are 
proposed to underlie the development of raised ICP in 
ALF)[52]. Furthermore, in the group of patients who did 
not require specific therapy for raised ICP, increases 
in the number of SIRS components fulfilled, CRP and 
TNF-α were associated with the development of surges 
of increased ICP[52]. These findings confirm that both 
systemic and local inflammation is important in the 
pathogenesis of the raised ICP of ALF. The acquisition 
of infection (with or without the development of SIRS) 
during grade I-II HE has been shown to be predictive 
of worsening HE in a group of patients with APAP-
ALF, but interestingly not in patients with non-APAP 
ALF[31]. Despite this, Vaquero reported that detection 
of infection during the early stage of HE was not 
associated with a poorer outcome[31]. These findings 
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raise the possibility that prophylactic antibiotics might 
benefit patients with APAP-ALF and early HE. 
Recognition of the role of neuroinflammation and 
infection in the progression of HE allows the development 
of pathophysiologically based management strategies. 
As infection and SIRS appear to be intrinsically linked 
to the development and progression of HE, stringent 
microbiological surveillance and prompt treatment of 
infection are a cornerstone in management of HE in 
ALF. With regards to novel therapies, as TNF-α has been 
demonstrated to be involved in the development of 
HE, the use of albumin dialysis to facilitate removal of 
TNF-α has been proposed[64]. In animal models of ALF, 
etanercept (an anti TNF-α molecule) prevents microglial 
activation and IL-6 accumulation, delaying the onset of 
HE and cerebral edema[65]. It may be that etanercept 
provides a new therapeutic target for the patient with 
ALF, but primarily the role of TNF-α and related genetic 
polymorphisms in human ALF needs to be confirmed. 
Other novel therapies targeting neuroinflammation 
in ALF include N-acetylcysteine (NAC) and minocycline. 
NAC crosses the BBB, and is reported to have anti-
inflammatory properties[66]. NAC presumably has 
both peripheral and central actions, and has been 
shown to slow progression of HE and prevent cerebral 
edema[67,68]. Minocycline is a tetracycline antibiotic 
that appears to prevent microglial activation, which 
is known to be a major factor in the development of 
HE[69]. The role of indomethacin - a cyclo-oxygenase 
inhibitor - has also been studied; it appears to prevent 
the effects of cytokines on cerebrovascular endothelial 
cells, which form the BBB[70]. The latter two therapies 
have been studied predominantly in animal models of 
ALF, and as yet their therapeutic benefit has not been 
translated to human practice. 
INfeCTION, INfLAmmATION AND ReNAL 
DysfUNCTION
Renal failure is a common complication of ALF (more 
common in APAP-ALF than non-APAP ALF, at least in 
part due to direct renal toxicity caused by APAP)[50], and 
is associated with increased mortality[71]. Despite the 
clear prognostic importance of the development of renal 
dysfunction, the pathogenesis is not well understood. 
Some schools of thought believe that the renal 
dysfunction of ALF shares similar pathophysiological 
mechanisms to the hepatorenal syndrome of chronic 
liver disease[72]. As SIRS has been shown to contribute 
to the development and progression of HE and 
multiorgan failure, it has been proposed that the 
SIRS response may also be implicated in the specific 
development of renal dysfunction in ALF. The systemic 
inflammatory response stimulates apoptotic death 
of renal tubular cells[73], and both TNF-α and IL-6 
contribute to hemodynamic disturbance in ALF, which 
may lead to pre-renal acute kidney injury (AKI)[74].
Studying a cohort of 308 patients with ALF, Leithead 
reported that 70% of patients demonstrated a SIRS 
response; overall, SIRS was more prevalent in the 
APAP-ALF cohort and was not affected by the presence 
of infection[50]. Those patients with APAP-ALF were 
more likely to develop renal dysfunction (as defined by 
the RIFLE criteria) than those with non-APAP ALF and 
this likely relates in part to a direct nephrotoxic effect 
of acetaminophen. Overall, patients who developed 
renal dysfunction demonstrated a greater systemic 
inflammatory response, with an increasing number 
of SIRS components fulfilled being associated with 
an increased probability of renal dysfunction. 78% of 
AKI patients developed SIRS, compared with 53% 
of the non-AKI patients and on multivariate analysis 
SIRS remained an independent risk factor for the 
development of AKI[50]. Patients with renal dysfunction 
were also were also more likely to demonstrate 
infection and superadded infection was associated with 
development of AKI; in both those with and without 
infection, SIRS was more common in the AKI patients. 
The risk of developing AKI and the impact of SIRS is 
different in the APAP-ALF and non APAP-ALF cohorts. 
In APAP-ALF, patients developing AKI were not more 
likely to have a SIRS response, and they were not 
more likely to have infection. In contrast, in non-APAP 
ALF there was a strong association between SIRS and 
renal dysfunction[50]. 
The relationship between pro-inflammatory 
mediators, SIRS and renal dysfunction in ALF suggest 
that the inflammatory cascade is central to the 
development of renal dysfunction. Therapies which 
target this inflammatory response may therefore be 
vital in preventing the development and halting the 
progression of AKI in ALF, affording a subsequent 
mortality benefit. 
BIOmARkeRs Of INfeCTION AND 
INfLAmmATION IN ALf
There remains an urgent need for dynamic, easy 
to apply ALF- specific biomarkers that can be used 
for predicting prognosis in ALF, as currently applied 
prognostic scoring systems fall short on negative 
predictive value and specificity. Recently, a multitude 
of biomarkers reflecting the important role of 
inflammation and infection in the pathogenesis and 
prognosis of ALF have been proposed and studied- 
see Table 2[75-80]. The majority of biomarkers described 
in the table remain research tools at present. 
However, the neutrophil-lymphocyte ratio (NLR) has 
been proposed as an important marker of systemic 
inflammation. This marker is rapidly available and 
cost effective as it can be calculated from routine 
laboratory tests. The NLR has been studied in other 
inflammatory conditions, and found to be of prognostic 
value[81,82]. In ALF, NLR has been studied in single time 
point and staggered APAP overdose[83]. Craig reported 
that median NLR was higher at 72 and 96 h post 
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overdose in single time point overdoses in patients 
who subsequently either died or were transplanted 
compared with those who spontaneously survived. 
A NLR > 16.7 during first 96 h following overdose 
correlated with the development of HE. Interestingly 
however, in the staggered overdose cohort, NLR 
was not predictive of adverse outcomes either at 
admission or subsequently[83]. Future human research 
studies should make identification and validation of 
a pathophysiologically based biomarker a priority, to 
assist in decision making regarding need for urgent 
liver transplantation.
RemAININg pROBLems AND fUTURe 
ReseARCH DIReCTIONs
A better understanding of the pathophysiology of 
ALF- including the individual components involved in 
immune dysregulation and the role of infection- is vital 
to the development of novel treatments. Increasing 
understanding of the underlying pathophysiological 
mechanisms of acute liver injury and resolution in 
mouse models gives rise to the hope of developing 
new treatment options in humans, in whom currently 
liver transplantation is the only curative treatment, 
yet limited by organ availability and patient suitability. 
Monocyte and macrophage numbers and function may 
be the key and should be a priority focus in human 
research. Targeting cytokines proven to play a role in 
human ALF is also pivotal. However, some concern 
has also been raised about trialling such therapies 
due to a potential risk of infection, in patients who are 
already at higher risk of acquiring bacterial or fungal 
infection. Much work needs to be undertaken in the 
field of immunology and infection before ALF becomes 
a treatable disease without the requirement for organ 
transplantation.
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